Latest news with #2025InnovationShowcase
Yahoo
24-07-2025
- Health
- Yahoo
Merakris Therapeutics Spotlights Investigational New Drug, MTX-001, with Innovation Showcase Win at 2025 Advanced Wound Care Summit
MTX-001 recognized for its clinical and commercial potential for treating chronic non-healing venous leg ulcers (VLUs) RESEARCH TRIANGLE PARK, N.C., July 24, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics announces it was selected as the winner of the 2025 Innovation Showcase at the Advanced Wound Care (AWC) Summit held last week in Boston. The award recognizes the most promising early-stage disruptive technology in wound care. During the showcase, Merakris CEO Chris Broderick presented MTX-001, a first-in-class injectable biologic drug therapy derived from purified amniotic fluid for the treatment of non-healing venous leg ulcers (VLUs) including: Total Addressable Market (TAM)/market opportunity & payer strategy Key findings from ongoing Phase 2 clinical trial of investigational new drug MTX-001 Mechanisms of action Production scale manufacturing plan A panel of industry experts selected Merakris for the award based on several criteria including clinical innovation, therapeutic potential, commercialization strategy, and overall impact on the wound care landscape. 'Standard therapies continue to fail many patients suffering from non-healing VLUs,' said Broderick. 'Merakris is pioneering MTX-001 and developing a new class of regenerative biologics that address chronic wound closure. We're honored to be recognized by the AWC Summit for our work to advance care in this underserved patient population.' For strategic partnership and collaboration opportunities, please visit For more information about the MTX-001 clinical trial or Merakris' Expanded Access Program, please contact medaffairs@ About Merakris Therapeutics Merakris Therapeutics is a leading innovator in regenerative medicine focused on developing and commercializing biologically derived products for wound healing and other complex conditions. Leveraging advanced biologic manufacturing capabilities and a robust research pipeline, Merakris is committed to improving patient outcomes and advancing the science of regenerative therapies. Merakris Forward Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of Merakris' products, or regarding potential future revenues from any such product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Merakris' management believes that any forward-looking statements in this press release are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Merakris, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and advisors and on the global economy as a whole. Investigational drug tradename (Dermacyte Liquid or Dermacyte Amniotic Wound Care Liquid) has not been approved by FDA. CONTACT: Contact Michelle Murray michelle@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Toronto Star
24-07-2025
- Business
- Toronto Star
Merakris Therapeutics Spotlights Investigational New Drug, MTX-001, with Innovation Showcase Win at 2025 Advanced Wound Care Summit
RESEARCH TRIANGLE PARK, N.C., July 24, 2025 (GLOBE NEWSWIRE) — Merakris Therapeutics announces it was selected as the winner of the 2025 Innovation Showcase at the Advanced Wound Care (AWC) Summit held last week in Boston. The award recognizes the most promising early-stage disruptive technology in wound care. During the showcase, Merakris CEO Chris Broderick presented MTX-001, a first-in-class injectable biologic drug therapy derived from purified amniotic fluid for the treatment of non-healing venous leg ulcers (VLUs) including:
Hamilton Spectator
24-07-2025
- Business
- Hamilton Spectator
Merakris Therapeutics Spotlights Investigational New Drug, MTX-001, with Innovation Showcase Win at 2025 Advanced Wound Care Summit
RESEARCH TRIANGLE PARK, N.C., July 24, 2025 (GLOBE NEWSWIRE) — Merakris Therapeutics announces it was selected as the winner of the 2025 Innovation Showcase at the Advanced Wound Care (AWC) Summit held last week in Boston. The award recognizes the most promising early-stage disruptive technology in wound care. During the showcase, Merakris CEO Chris Broderick presented MTX-001, a first-in-class injectable biologic drug therapy derived from purified amniotic fluid for the treatment of non-healing venous leg ulcers (VLUs) including: A panel of industry experts selected Merakris for the award based on several criteria including clinical innovation, therapeutic potential, commercialization strategy, and overall impact on the wound care landscape. 'Standard therapies continue to fail many patients suffering from non-healing VLUs,' said Broderick. 'Merakris is pioneering MTX-001 and developing a new class of regenerative biologics that address chronic wound closure. We're honored to be recognized by the AWC Summit for our work to advance care in this underserved patient population.' For strategic partnership and collaboration opportunities, please visit . For more information about the MTX-001 clinical trial or Merakris' Expanded Access Program, please contact medaffairs@ . About Merakris Therapeutics Merakris Therapeutics is a leading innovator in regenerative medicine focused on developing and commercializing biologically derived products for wound healing and other complex conditions. Leveraging advanced biologic manufacturing capabilities and a robust research pipeline, Merakris is committed to improving patient outcomes and advancing the science of regenerative therapies. Merakris Forward Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of Merakris' products, or regarding potential future revenues from any such product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Merakris' management believes that any forward-looking statements in this press release are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Merakris, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and advisors and on the global economy as a whole. Investigational drug tradename (Dermacyte Liquid or Dermacyte Amniotic Wound Care Liquid) has not been approved by FDA.
Yahoo
30-04-2025
- Business
- Yahoo
MIT Sloan CIO Symposium Selects Finalists for 2025 Innovation Showcase
Winners include early-stage companies in artificial intelligence, cybersecurity and data CAMBRIDGE, Mass., April 30, 2025 /PRNewswire/ -- The 22nd annual MIT Sloan CIO Symposium, today announced the 10 finalists for its 2025 Innovation Showcase. The selected outstanding early-stage companies have developed cutting-edge solutions that combine both value and innovation to the Enterprise IT space. The finalists will receive key exposure to many of the world's most creative and influential IT executives at the in-person Symposium from May 19-20, 2025. "We are excited to introduce the finalists for the 2025 Innovation Showcase, an annual highlight of the MIT Sloan CIO Symposium," said Anton Teodorescu, Chair of the Innovation Showcase. "It's an honor to continue to support emerging enterprises as they connect with industry leaders, fostering collaborations that consistently drive meaningful innovation and mutual success." The 10 Innovation Showcase Finalists for 2025 are: Aperio–Boston, Massachusetts Aperio addresses the top barrier to industrial AI by delivering scalable, trusted Data Quality that enables analytics, compliance, and efficiency. Arundo Analytics–Houston, TexasDelivering AI solutions and virtual assistant technology to drive excellence in asset heavy industries. Simplifying operations, accelerating decisions. Bluumly–San Clemente, CaliforniaBluumly is an AI-powered marketing platform that transforms how micro-businesses create, optimize and execute digital marketing across all channels. DataTrails–Santa Clara, CaliforniaDataTrails – Provenance Signed, Sealed, Delivered. It's no wonder responsible businesses rely on us. DBOS–Boston, MassachusettsDBOS is a durable computing system that simplifies software development and protects the business from the effects of software crashes and errors FenixPyre–New Albany, OhioFenixPyre delivers seamless, zero-trust file-centric security, transparently encrypting data at rest, in transit, and in use. iCustomer–Cambridge, MassachusettsiCustomer enables semantic enrichment, multi-agent AI orchestration with privacy guardrails—activating enterprise customer data for smarter, Marketing decisions & growth. Narratize–Covington, KentuckyNarratize is the AI-powered product intelligence platform that transforms scattered knowledge into market-ready innovations, accelerating development by 46%. Silverthread–Cambridge, MassachusettsSilverthread helps software teams modernize systems by improving code quality and architecture for better maintainability, agility, and decision-making. Skyline Nav–Cambridge, MassachusettsSkyline Nav AI delivers precise, GPS-independent navigation for land and air using computer vision and satellite data—no connectivity required. After careful consideration, the Innovation Showcase judges selected these 10 impressive companies because they: Have an enterprise IT solution product available in the market Are a start-up with less than $10 million in annual revenues Are selling enterprise IT solutions to CIOs or corporate IT departments Show innovation and/or strategic value and potential impact on the top and/or bottom lines The Innovation Showcase will take place at The Royal Sonesta in Cambridge, Massachusetts on May 20, 2025. The full agenda for the MIT Sloan CIO Symposium is available at and tickets are available for purchase at About the MIT Sloan CIO SymposiumThe MIT Sloan CIO Symposium is the premier global conference for CIOs and digital business executives to become more effective leaders. CIOs and senior IT executives explore enterprise technology innovations, business practices and receive actionable information that enables them to meet the challenges of today and the future. The Symposium offers a unique learning environment by bringing together the academic thought leadership of MIT with the in-the-trenches experience of leading global CIOs and industry experts. The MIT Sloan CIO Symposium is organized and developed by the MIT Sloan Boston Alumni Association. For more information and to register for this year's Symposium, visit Editor's Note:Journalists interested in press credentials or speaking with any of the Showcase Innovation finalists should contact Kim Schaefer, Warner Communications, at kim@ View original content to download multimedia: SOURCE MIT Sloan CIO Symposium Sign in to access your portfolio
